GH Research (NASDAQ:GHRS) Shares Down 0.3% – Here’s Why

Shares of GH Research PLC (NASDAQ:GHRS) fell 0.3% during trading on Friday . The stock traded as low as $8.60 and last traded at $9.25. 14,904 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 79,041 shares. The stock had previously closed at $9.28.

Wall Street Analyst Weigh In

Several research firms recently commented on GHRS. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research report on Wednesday, November 20th. JMP Securities reiterated a “market outperform” rating and issued a $39.00 price target on shares of GH Research in a research report on Wednesday, September 4th. Finally, Canaccord Genuity Group reduced their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, November 18th.

GH Research Stock Performance

The company has a market cap of $480.76 million, a PE ratio of -11.71 and a beta of 0.74. The stock’s 50-day simple moving average is $7.98 and its 200 day simple moving average is $10.23.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. On average, sell-side analysts predict that GH Research PLC will post -0.79 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. increased its stake in GH Research PLC (NASDAQ:GHRS) by 1.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,686,689 shares of the company’s stock after purchasing an additional 85,000 shares during the quarter. RA Capital Management L.P. owned 12.85% of GH Research worth $44,734,000 at the end of the most recent quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).